Download PDF
Nuklearmedizin 1999; 38(01): 1-6
DOI: 10.1055/s-0038-1632181
Originalarbeiten — Original Articles
Schattauer GmbH

F-18-FDG-PET bei Schilddrüsen-Autonomien

F-18-FDG-PET in Autonomous Goiter
Anne-Rose Börner
1   Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln
,
E. Voth
1   Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln
,
K. Wienhard
2   Max-Planck-Institut für Neurologische Forschung, Köln, Deutschland
,
R. Wagner
2   Max-Planck-Institut für Neurologische Forschung, Köln, Deutschland
,
H. Schicha
1   Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln
› Author Affiliations
Further Information

Publication History

Eingegangen: 23 July 1998

in revidierter Form: 11 September 1998

Publication Date:
03 February 2018 (online)

    Permissions and Reprints

Zusammenfassung:

Ziel: Die Schilddrüsenautonomie im lodmangelgebiet beruht in der Mehrzahl der Fälle auf konstitutiven, funktionsaktivierenden Mutationen des Thyreotropin-(TSH-)Rezeptors. Diese Studie evaluiert F-18-Fluoro-Deoxy-Glukose-(F-18-FDG-)PET der Schilddrüse bei Patienten mit funktionell relevanter Autonomie der Schilddrüse. Methoden: 20 Patienten mit fokaler und 10 Patienten mit disseminierter Autonomie der Schilddrüse wurden am Tag vor geplanter Radioiod-Therapie mit FDG-PET untersucht. 20 Patienten mit Kopf/Halstumoren und normaler Schilddrüsenfunktion dienten als Kontrollgruppe. Ergebnisse: Die F-18-FDG-Aufnahme in die Schilddrüse war signifikant höher bei Patienten mit funktionell relevanter Autonomie im Vergleich zu den Kontrollen. Fokale Autonomien zeichneten sich ausnahmslos durch einen intensiven, fokal gesteigerten Glukose-Uptake aus, während disseminierte Autonomien ein variables Muster globaler Steigerungen des Glukose-Uptakes zeigten. Schlußfolgerung: Funktionelle Autonomien der Schilddrüse zeigen einen gleichzeitig gesteigerten Glukose- und lodstoffwechsel als Folge der konstitutiven Mutation des TSH-Rezeptors, wobei das Ausmaß beider Veränderungen positiv korreliert.

Summary

Aim: Gain-of-function mutations of the thyrotropin receptor (TSHR) gene have been invoked as one of the major causes of toxic thyroid adenomas. This study evaluates F-18-FDG-PET in these patients. Methods: Twenty patients with focal autonomous nodules and ten with disseminated autonomy were investigated the day before radioiodine therapy. Twenty patients with cancer of the head or neck and normal thyroid function served as controls. Results: F-18-FDG-Uptake was higher in patients than in controls. Focal autonomous nodules were associated with focally enhanced glucose metabolism. Disseminated autonomous goiters showed various patterns of focal or global hypermetabolism. Conclusion: Autonomous thyroid tissue caused by constitutive mutations of the TSH receptor is characterised by simultaneous increases in glucose and iodine metabolism which are correlated.

Schlüsselwörter

Schilddrüsenautonomie - Glukosemetabolismus - FDG-PET - TSH - konstitutive Rezeptormutat

Key words

Autonomous goiter - glucose metabolism - FDG-PET - TSH - constitutive receptor mutation
 

  • Literatur

  • 1 Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993; 3: 195-200.
    CrossrefPubMedGoogle Scholar
  • 2 Als C, Listewnik M, Ritter HP, Rosler H. Scintigraphic method in the quantification of morphological and functional changes of thyroid autonomy before and after iodine radiotherapy. Schweiz Med Wochenschr 1997; 127: 102-6.
    PubMedGoogle Scholar
  • 3 Bähre M, Hilgers R, Lindemann C, Emrich D. Thyroid autonomy: sensitive detection in vivo and estimation of its functional relevance using quantified high-resolution scintigraphy. Acta Endocrinol (Copenh) 1988; 117: 145-53.
    PubMedGoogle Scholar
  • 4 Becker W, Börner W, Rendl J. Is a TSH screening for the diagnosis or exclusion of functional thyroid autonomy meaningful?. Nuklearmedizin 1992; 31 (04) 132-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Börner AR, Voth E, Wienhard K, Wagner R, Schicha H. F-18-FDG-PET der Schilddrüse bei M. Basedow. Nuklearmedizin. 1998 (in Druck).
    PubMedGoogle Scholar
  • 6 Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-60.
    CrossrefPubMedGoogle Scholar
  • 7 Dederichs B, Otte R, Klink JE, Schicha H. Volumenreduktion der Schilddrüse nach Radioiodtherapie bei Patienten mit Schilddrüsenautonomie und M. Basedow. Nuklearmedizin 1996; 35: 164-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Derwahl M, Hamacher C, Russo D, Broecker M, Manole D, Schatz H, Kopp P, Filetti S. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. J Clin Endocrinol Metab 1996; 81: 1898-904.
    PubMedGoogle Scholar
  • 9 Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Diagnostische Algorithmen in der Nachsorge des differenzierten Schilddrüsenkarzinoms: Welchen Stellenwert haben FDG und Sestamibi?. Nuklearmedizin 1998; 37: 6-11.
    Article in Thieme ConnectGoogle Scholar
  • 10 Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18-fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 1341-8.
    Google Scholar
  • 11 Endo T, Shimura H, Saito T, Ikeda M, Ohmori M, Onaya T. Thyreotropin stimulates glucose regulated protein (GRP78) gene expression in rat functional thyroid epithelial cells, FRTL. Mol Endocrinol 1991; 5: 905-10.
    CrossrefPubMedGoogle Scholar
  • 12 Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W. F-18-FDG-Ganzkörper-PET bei differenzierten Schilddrüsenkarzinomen. Nuklearmedizin 1995; 34: 127-34.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Field JB. Intermediary metabolism of the thyroid. In: Greep RO, Astwood EB. eds. Handbook of Physiology, Section 7: Endocrinology, Part III: Thyroid. Washington: American Physiological Society; 1974: 147-59.
    Google Scholar
  • 14 Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinoloy 1987; 120: 2576-81.
    CrossrefPubMedGoogle Scholar
  • 15 Flower MA, Al-Saadi A, Harmer CL, McReady VR, Ott RJ. Dose-response study on thyreotoxic patients undergoing positron emission tomography and radioiodine therapy. Eur J Nucl Med 1994; 21: 531-6.
    PubMedGoogle Scholar
  • 16 Gerber H, Peter HJ, Ramelli F, Miloni E, König MP, Studer H, Berchthold R, Gemsenjäger E. Autonomie und Heterogenität der Follikel in der euthyreoten und hyperthyreoten menschlichen Knotenstruma: die Lösung alter Rätsel?. Schweiz Med Wschr 1983; 113: 1178-87.
    PubMedGoogle Scholar
  • 17 Gerber H, Bürgi U, Peter HJ. Etiology and pathogenesis of thyroid nodules. Exp Clin Endocrinol 1993; 101: 97-101.
    Google Scholar
  • 18 Grünwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J, Franckson T, Biersack HJ. Comparison of F-18-FDG-PET with 131-iodine and 99m-Tc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997; 7: 327-35.
    CrossrefPubMedGoogle Scholar
  • 19 Hawkins RA, Höh CK. PET FDG studies in oncology. Nucl Med Biol 1994; 21: 739-47.
    CrossrefPubMedGoogle Scholar
  • 20 Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987; 28: 910-4.
    PubMedGoogle Scholar
  • 21 Joseph K. Diagnosis and therapy of functional autonomy. Acta Med Austriaca 1990; 17 (Suppl. 01) 47-53.
    PubMedGoogle Scholar
  • 22 Krohn K, Fuhrer D, Holzapfel HP, Paschke R. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 1998; 83: 130-4.
    CrossrefPubMedGoogle Scholar
  • 23 Luster M, Jacob M, Thelen MH, Michalowski U, Deutsch U, Reiners C. Reduction of thyroid volume following radioiodine therapy for functional autonomy. Nuklearmedizin 1995; 34: 57-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Moka D, Voth E, Schicha H. Effect of antithyroid medication on the effective halflife and uptake of 131-iodine following radioiodine therapy. Nuklearmedizin 1997; 36: 87-92.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, Costagliola S, Rodien P, Dumont JE, Vassart G. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997; 82: 2695-701.
    PubMedGoogle Scholar
  • 26 Parma J, Van Sande J, Swillens S, Tonacchera M, Dumont J, Vassart G. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3’,5’-monophosphate and inositol phosphate-Ca2+-cascades. Mol Endocrinol 1995; 9: 725-33.
    PubMedGoogle Scholar
  • 27 Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. N Engl J Med 1997; 337: 1675-81.
    CrossrefPubMedGoogle Scholar
  • 28 Paschke R. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Exp Clin Endocrinol Diabetes 1996; 104 (Suppl): 129-32.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Pinducciu C, Borgonovo G, Arezzo A, Torre GC, Giordano G, Cordera R. Toxic thyroid adenoma: absence of DNA mutations of the TSH receptor and Gs alpha. Eur J Endocrinol 1998; 138: 37-40.
    CrossrefPubMedGoogle Scholar
  • 30 Porcellini A, Fenzi G, Avvedimento EV. Mutations of thyrotropin receptor gene. J Mol Med 1997; 75: 567-75.
    CrossrefPubMedGoogle Scholar
  • 31 Reinhardt MJ, Moser E. An update on diagnostic methods in the investigation of diseases of the thyroid. Eur J Nucl Med 1996; 23: 587-94.
    CrossrefPubMedGoogle Scholar
  • 32 Russo D, Arturi F, Suarez HG, Schlumberger M, Du VJ, Crocetti U, Filetti S. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1996; 81: 1548-51.
    PubMedGoogle Scholar
  • 33 Studer H, Peter HJ, Gerber H. Morphologie and functional changes in developing goiters. In: Hall R, Köbberling J. (eds). Thyroid disorders associated with iodine deficiency and excess. New York: 1985: 227-40.
    Google Scholar
  • 34 Sachs L. Angewandte Statistik. 6. Aufl.. Berlin, Heidelberg, New York, Tokio: Springer-Verlag; 1984
    Google Scholar
  • 35 Sanders J, Oda Y, Roberts SA, Maruyama M, Furmaniak J, Smith BR. Understanding the thyrotropin receptor function-structure relationship. Baillieres Clin Endocrinol Metab 1997; 11: 451-79.
    CrossrefPubMedGoogle Scholar
  • 36 Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, Masuda K. An evaluation of FDG-PET in the detection and differentiation of thyroid tumours. Nucl Med Comm 1997; 18: 957-63.
    CrossrefPubMedGoogle Scholar
  • 37 Siegel RD, Lee SL. Toxic nodular goiter. Toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin North Am 1998; 27: 151-68.
    CrossrefPubMedGoogle Scholar
  • 38 Sisson JC, Ackermann RJ, Meyer MA, Wahl RL. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993; 77: 1090-4.
    PubMedGoogle Scholar
  • 39 Thomson FJ, Jess TJ, Moyes C, Plevin R, Gould GW. Characterization of the intracellular signalling pathways that underlie growth-factor-stimulated glucose transport in Xenopus oocytes: evidence for ras-and rho-dependent pathways of phosphatidylinositol-3-kinase activation. Biochem J 1997; 325: 637-43.
    CrossrefPubMedGoogle Scholar
  • 40 Tonacchera M, Chiovato L, Pinchera A, Agretti P, Fiore E, Cetani F, Rocchi R, Viacava P, Miccoli P, Vitti P. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab 1998; 83: 492-8.
    PubMedGoogle Scholar
  • 41 Utiger RD. Thyrotropin-receptor mutations and thyroid dysfunction. N Engl J Med 1995; 332: 183-5.
    CrossrefPubMedGoogle Scholar
  • 42 Vassart G, Van Sande J, Parma J, Tonacchera M, Duprez L, Swillens S, Dumont J. Activating mutations of the TSH receptor gene cause thyroid diseases. Ann Endocrinol 1996; 57: 50-4.
    Google Scholar
  • 43 Vassart G. New pathophysiological mechanisms for hyperthyroidism. Horm Res 1997; 48 (Suppl): 47-50.
    PubMedGoogle Scholar
  • 44 Voth E, Börner AR, Theissen P, Schicha H. Positron emission tomography (PET) in benign thyroid diseases. Exp Clin Endocrinol 1994; 102 (Suppl. 03) 71-4.
    Google Scholar
  • 45 Yao WJ, Hoh CK, Hawkins RA, Glaspy JA, Weil JA, Lee SJ, Maddahi J, Phelps ME. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med 1994; 36: 794-9.
    Google Scholar
  • 46 Zasadny KR, Wahl RL. Standardizes uptake values of normal tissues at PET with 2-[Fluorine-18]-Fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 1993; 189: 847-50.
    CrossrefPubMedGoogle Scholar